Shots: MiNA and AstraZeneca will conduct in vitro and in vivo studies allowing the development of saRNA therapies for Metabolic Diseases. Post the completion of the studies, AstraZeneca will have […]readmore
Tags : Research
Shots: Roche and Sensyne Health collaborate to apply AI technology for clinical trial designs and will further strengthen Roche’s approach in data and technology-driven personalized healthcare The collaboration will focus […]readmore
Shots: Pfizer has selected its second target under the research and license agreement signed by the companies in 2016 and has extended the research term by six months BioInvent to […]readmore
Shots: Eisai and BioArctic collaborate to further characterize the MOA of BAN2401. Earlier in 2005, the companies partnered for the therapy targeting Alzheimer’s disease and later in 2007, BioArctic licensed […]readmore
Shots: Vyriad to receive upfront, development and commercial milestone payments based on certain achievements and royalties on sales of products. Regeneron to get an exclusive option to license Vyriad’s Voyager-V1 […]readmore
Shots: Takeda to get rights to develop and commercialize up to four programs including a CD19-targeted CAR NK-cell therapy and a B-cell maturation antigen (BCMA)-targeted CAR NK-cell therapy and will […]readmore
Shots: Bluebird Bio to utilize its mRNA-based megaTAL technology providing a specific and efficient way to silence, edit or insert genetic components combining Novo Nordisk’s deep expertise in hemophilia research […]readmore
Shots: 4D to receive up front in cash for each indication, ~$347.5M as option exercise fee, development & commercialization milestones with royalties on sales of licensed product derived from the […]readmore
Shots: Numab to receive up front, research funding, success fees, milestones & royalties on sales. Eisai to get an option to acquire an exclusive license to develop and commercialize novel […]readmore
Shots: Novartis to get an option to acquire IFM Due (a subsidiary of IFM Therapeutics) in exchange of funding for research & development of cGAS/STING program. Post exercising of option, […]readmore